ACRS Aclaris Therapeutics Inc.

7.31
-0.34  -4%
Previous Close 7.65
Open 7.56
Price To Book 2.05
Market Cap 299243556
Shares 40,936,191
Volume 1,684,753
Short Ratio
Av. Daily Volume 526,679

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2019.
ATI-502 (AA-201 Topical) - dose ranging
Alopecia areata
Phase 2 open label data due 1H 2019.
ATI-502 (VITI-201 Topical)
Vitiligo
Phase 2 trial ongoing.
ATI-502 AUATB-201 - open label
Alopecia areata - regrowth of eyebrows
Phase 2 data due 2H 2019.
ATI-501 (AUAT-201 Oral)
Alopecia areata
Approval announced December 15, 2017.
ESKATA (hydrogen peroxide)
Seborrheic keratosis (SK)
Phase 3 data due 2H 2019.
A-101 THWART-1 and THWART-2
Common warts (verruca vulgaris)
Phase 2 interim data released June 28, 2018.
ATI-502 AA-202 Topical - PK/safety
Alopecia areata
Phase 2 data due 1H 2019.
ATI-502 - open label
Androgenetic alopecia (AGA) - Hair loss
Phase 2 data due mid-2019.
ATI-502
Atopic dermatitis (AD)

Latest News

  1. Aclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan
  2. Aclaris Therapeutics (ACRS) Enters Oversold Territory
  3. Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
  4. Edited Transcript of ACRS earnings conference call or presentation 6-Nov-18 10:00pm GMT
  5. Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
  6. Aclaris: 3Q Earnings Snapshot
  7. Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
  8. Aclaris Therapeutics to Attend Upcoming Investor Conferences
  9. Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for
  10. Aclaris Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018
  11. One Thing To Remember About The Aclaris Therapeutics Inc (NASDAQ:ACRS) Share Price
  12. Aclaris Announces Closing of Public Offering of Common Stock
  13. Aclaris plans $92.9M public stock offering
  14. Aclaris Announces Pricing of Public Offering of Common Stock
  15. Aclaris Announces Proposed Public Offering of Common Stock
  16. The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise
  17. Edited Transcript of ACRS earnings conference call or presentation 15-Oct-18 9:00pm GMT
  18. $65 million deal: Aclaris buying rights to rosacea drug from Allergan